CovidChloroV1, Main, Corpus, bibRecord, 001654

Neuroleptic malignant syndrome in a COVID-19 patient.

Identifieur interne : 001654 ( Main/Corpus ); précédent : 001653; suivant : 001655

Neuroleptic malignant syndrome in a COVID-19 patient.

Auteurs : Raahil Kajani ; Austin Apramian ; Arturo Vega ; Nitin Ubhayakar ; Prissilla Xu ; Antonio Liu

Source :

Brain, behavior, and immunity [ 1090-2139 ] ; 2020.

RBID : pubmed:32425332

English descriptors

KwdEn :
- Acute Kidney Injury (etiology), Acute Kidney Injury (therapy), Antipsychotic Agents (adverse effects), Betacoronavirus (MeSH), Bromocriptine (therapeutic use), C-Reactive Protein (immunology), COVID-19 (MeSH), Coronavirus Infections (complications), Coronavirus Infections (immunology), Coronavirus Infections (physiopathology), Coronavirus Infections (therapy), Dantrolene (therapeutic use), Dopamine Agonists (therapeutic use), Enzyme Inhibitors (therapeutic use), Haloperidol (adverse effects), Haloperidol (analogs & derivatives), Humans (MeSH), Hydroxychloroquine (therapeutic use), Intensive Care Units (MeSH), Leukocytosis (MeSH), Lymphopenia (MeSH), Male (MeSH), Middle Aged (MeSH), Muscle Relaxants, Central (therapeutic use), Neuroleptic Malignant Syndrome (etiology), Neuroleptic Malignant Syndrome (physiopathology), Neuroleptic Malignant Syndrome (therapy), Pandemics (MeSH), Pneumonia, Viral (complications), Pneumonia, Viral (immunology), Pneumonia, Viral (physiopathology), Pneumonia, Viral (therapy), Renal Dialysis (MeSH), Respiration, Artificial (MeSH), Rhabdomyolysis (etiology), Rhabdomyolysis (therapy), SARS-CoV-2 (MeSH), Schizophrenia (complications), Schizophrenia (drug therapy).
MESH :
- chemical , adverse effects : Antipsychotic Agents, Haloperidol.
- chemical , analogs & derivatives : Haloperidol.
- complications : Coronavirus Infections, Pneumonia, Viral, Schizophrenia.
- drug therapy : Schizophrenia.
- etiology : Acute Kidney Injury, Neuroleptic Malignant Syndrome, Rhabdomyolysis.
- chemical , immunology : C-Reactive Protein, Coronavirus Infections, Pneumonia, Viral.
- physiopathology : Coronavirus Infections, Neuroleptic Malignant Syndrome, Pneumonia, Viral.
- chemical , therapeutic use : Bromocriptine, Dantrolene, Dopamine Agonists, Enzyme Inhibitors, Hydroxychloroquine, Muscle Relaxants, Central.
- therapy : Acute Kidney Injury, Coronavirus Infections, Neuroleptic Malignant Syndrome, Pneumonia, Viral, Rhabdomyolysis.
- Betacoronavirus, COVID-19, Humans, Intensive Care Units, Leukocytosis, Lymphopenia, Male, Middle Aged, Pandemics, Renal Dialysis, Respiration, Artificial, SARS-CoV-2.

DOI: 10.1016/j.bbi.2020.05.042
PubMed: 32425332
PubMed Central: PMC7232071

Links to Exploration step

pubmed:32425332

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Neuroleptic malignant syndrome in a COVID-19 patient.</title>
<author><name sortKey="Kajani, Raahil" sort="Kajani, Raahil" uniqKey="Kajani R" first="Raahil" last="Kajani">Raahil Kajani</name>
<affiliation><nlm:affiliation>Adventist Health White Memorial, Los Angeles, CA, United States.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Apramian, Austin" sort="Apramian, Austin" uniqKey="Apramian A" first="Austin" last="Apramian">Austin Apramian</name>
<affiliation><nlm:affiliation>Adventist Health White Memorial, Los Angeles, CA, United States.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Vega, Arturo" sort="Vega, Arturo" uniqKey="Vega A" first="Arturo" last="Vega">Arturo Vega</name>
<affiliation><nlm:affiliation>Adventist Health White Memorial, Los Angeles, CA, United States.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Ubhayakar, Nitin" sort="Ubhayakar, Nitin" uniqKey="Ubhayakar N" first="Nitin" last="Ubhayakar">Nitin Ubhayakar</name>
<affiliation><nlm:affiliation>Adventist Health White Memorial, Los Angeles, CA, United States.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Xu, Prissilla" sort="Xu, Prissilla" uniqKey="Xu P" first="Prissilla" last="Xu">Prissilla Xu</name>
<affiliation><nlm:affiliation>Adventist Health White Memorial, Los Angeles, CA, United States.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Liu, Antonio" sort="Liu, Antonio" uniqKey="Liu A" first="Antonio" last="Liu">Antonio Liu</name>
<affiliation><nlm:affiliation>Adventist Health White Memorial, Los Angeles, CA, United States.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32425332</idno>
<idno type="pmid">32425332</idno>
<idno type="doi">10.1016/j.bbi.2020.05.042</idno>
<idno type="pmc">PMC7232071</idno>
<idno type="wicri:Area/Main/Corpus">001654</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001654</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Neuroleptic malignant syndrome in a COVID-19 patient.</title>
<author><name sortKey="Kajani, Raahil" sort="Kajani, Raahil" uniqKey="Kajani R" first="Raahil" last="Kajani">Raahil Kajani</name>
<affiliation><nlm:affiliation>Adventist Health White Memorial, Los Angeles, CA, United States.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Apramian, Austin" sort="Apramian, Austin" uniqKey="Apramian A" first="Austin" last="Apramian">Austin Apramian</name>
<affiliation><nlm:affiliation>Adventist Health White Memorial, Los Angeles, CA, United States.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Vega, Arturo" sort="Vega, Arturo" uniqKey="Vega A" first="Arturo" last="Vega">Arturo Vega</name>
<affiliation><nlm:affiliation>Adventist Health White Memorial, Los Angeles, CA, United States.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Ubhayakar, Nitin" sort="Ubhayakar, Nitin" uniqKey="Ubhayakar N" first="Nitin" last="Ubhayakar">Nitin Ubhayakar</name>
<affiliation><nlm:affiliation>Adventist Health White Memorial, Los Angeles, CA, United States.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Xu, Prissilla" sort="Xu, Prissilla" uniqKey="Xu P" first="Prissilla" last="Xu">Prissilla Xu</name>
<affiliation><nlm:affiliation>Adventist Health White Memorial, Los Angeles, CA, United States.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Liu, Antonio" sort="Liu, Antonio" uniqKey="Liu A" first="Antonio" last="Liu">Antonio Liu</name>
<affiliation><nlm:affiliation>Adventist Health White Memorial, Los Angeles, CA, United States.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Brain, behavior, and immunity</title>
<idno type="eISSN">1090-2139</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acute Kidney Injury (etiology)</term>
<term>Acute Kidney Injury (therapy)</term>
<term>Antipsychotic Agents (adverse effects)</term>
<term>Betacoronavirus (MeSH)</term>
<term>Bromocriptine (therapeutic use)</term>
<term>C-Reactive Protein (immunology)</term>
<term>COVID-19 (MeSH)</term>
<term>Coronavirus Infections (complications)</term>
<term>Coronavirus Infections (immunology)</term>
<term>Coronavirus Infections (physiopathology)</term>
<term>Coronavirus Infections (therapy)</term>
<term>Dantrolene (therapeutic use)</term>
<term>Dopamine Agonists (therapeutic use)</term>
<term>Enzyme Inhibitors (therapeutic use)</term>
<term>Haloperidol (adverse effects)</term>
<term>Haloperidol (analogs & derivatives)</term>
<term>Humans (MeSH)</term>
<term>Hydroxychloroquine (therapeutic use)</term>
<term>Intensive Care Units (MeSH)</term>
<term>Leukocytosis (MeSH)</term>
<term>Lymphopenia (MeSH)</term>
<term>Male (MeSH)</term>
<term>Middle Aged (MeSH)</term>
<term>Muscle Relaxants, Central (therapeutic use)</term>
<term>Neuroleptic Malignant Syndrome (etiology)</term>
<term>Neuroleptic Malignant Syndrome (physiopathology)</term>
<term>Neuroleptic Malignant Syndrome (therapy)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (complications)</term>
<term>Pneumonia, Viral (immunology)</term>
<term>Pneumonia, Viral (physiopathology)</term>
<term>Pneumonia, Viral (therapy)</term>
<term>Renal Dialysis (MeSH)</term>
<term>Respiration, Artificial (MeSH)</term>
<term>Rhabdomyolysis (etiology)</term>
<term>Rhabdomyolysis (therapy)</term>
<term>SARS-CoV-2 (MeSH)</term>
<term>Schizophrenia (complications)</term>
<term>Schizophrenia (drug therapy)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antipsychotic Agents</term>
<term>Haloperidol</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Haloperidol</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
<term>Schizophrenia</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Schizophrenia</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Acute Kidney Injury</term>
<term>Neuroleptic Malignant Syndrome</term>
<term>Rhabdomyolysis</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>C-Reactive Protein</term>
<term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Neuroleptic Malignant Syndrome</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Bromocriptine</term>
<term>Dantrolene</term>
<term>Dopamine Agonists</term>
<term>Enzyme Inhibitors</term>
<term>Hydroxychloroquine</term>
<term>Muscle Relaxants, Central</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Acute Kidney Injury</term>
<term>Coronavirus Infections</term>
<term>Neuroleptic Malignant Syndrome</term>
<term>Pneumonia, Viral</term>
<term>Rhabdomyolysis</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term>
<term>COVID-19</term>
<term>Humans</term>
<term>Intensive Care Units</term>
<term>Leukocytosis</term>
<term>Lymphopenia</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Pandemics</term>
<term>Renal Dialysis</term>
<term>Respiration, Artificial</term>
<term>SARS-CoV-2</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32425332</PMID>
<DateCompleted><Year>2020</Year>
<Month>08</Month>
<Day>14</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>01</Month>
<Day>27</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1090-2139</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>88</Volume>
<PubDate><Year>2020</Year>
<Month>08</Month>
</PubDate>
</JournalIssue>
<Title>Brain, behavior, and immunity</Title>
<ISOAbbreviation>Brain Behav Immun</ISOAbbreviation>
</Journal>
<ArticleTitle>Neuroleptic malignant syndrome in a COVID-19 patient.</ArticleTitle>
<Pagination><MedlinePgn>28-29</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S0889-1591(20)30838-2</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbi.2020.05.042</ELocationID>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kajani</LastName>
<ForeName>Raahil</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Adventist Health White Memorial, Los Angeles, CA, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Apramian</LastName>
<ForeName>Austin</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Adventist Health White Memorial, Los Angeles, CA, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Vega</LastName>
<ForeName>Arturo</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Adventist Health White Memorial, Los Angeles, CA, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ubhayakar</LastName>
<ForeName>Nitin</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>Adventist Health White Memorial, Los Angeles, CA, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Xu</LastName>
<ForeName>Prissilla</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Adventist Health White Memorial, Los Angeles, CA, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Liu</LastName>
<ForeName>Antonio</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Adventist Health White Memorial, Los Angeles, CA, United States.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>05</Month>
<Day>18</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Brain Behav Immun</MedlineTA>
<NlmUniqueID>8800478</NlmUniqueID>
<ISSNLinking>0889-1591</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009125">Muscle Relaxants, Central</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>3A64E3G5ZO</RegistryNumber>
<NameOfSubstance UI="D001971">Bromocriptine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber>
<NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>9007-41-4</RegistryNumber>
<NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>AC20PJ4101</RegistryNumber>
<NameOfSubstance UI="C033563">haloperidol decanoate</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>F64QU97QCR</RegistryNumber>
<NameOfSubstance UI="D003620">Dantrolene</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>J6292F8L3D</RegistryNumber>
<NameOfSubstance UI="D006220">Haloperidol</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D058186" MajorTopicYN="N">Acute Kidney Injury</DescriptorName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001971" MajorTopicYN="N">Bromocriptine</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002097" MajorTopicYN="N">C-Reactive Protein</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003620" MajorTopicYN="N">Dantrolene</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018491" MajorTopicYN="N">Dopamine Agonists</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006220" MajorTopicYN="N">Haloperidol</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007964" MajorTopicYN="N">Leukocytosis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008231" MajorTopicYN="N">Lymphopenia</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009125" MajorTopicYN="N">Muscle Relaxants, Central</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009459" MajorTopicYN="N">Neuroleptic Malignant Syndrome</DescriptorName>
<QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006435" MajorTopicYN="N">Renal Dialysis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012121" MajorTopicYN="N">Respiration, Artificial</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012206" MajorTopicYN="N">Rhabdomyolysis</DescriptorName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>05</Month>
<Day>06</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2020</Year>
<Month>05</Month>
<Day>14</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>05</Month>
<Day>14</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>5</Month>
<Day>20</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>8</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>5</Month>
<Day>20</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32425332</ArticleId>
<ArticleId IdType="doi">10.1016/j.bbi.2020.05.042</ArticleId>
<ArticleId IdType="pii">S0889-1591(20)30838-2</ArticleId>
<ArticleId IdType="pmc">PMC7232071</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001654 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001654 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:32425332
   |texte=   Neuroleptic malignant syndrome in a COVID-19 patient.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i   -Sk "pubmed:32425332" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021

	Serveur d'exploration COVID et hydrochloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration COVID et hydrochloroquine

Neuroleptic malignant syndrome in a COVID-19 patient.

Neuroleptic malignant syndrome in a COVID-19 patient.

Source :

English descriptors

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki